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Highlights 
 DYN 3-14 is the major fragment of DYN 1-17 produced in inflamed tissue.  
 DYN 3-14 inhibits NF-κB/p65 activation in response to LPS stimulation.  
 DYN 3-14 differentially modulates the release of IL-1β and TNF-α induced by LPS.   
 DYN 3-14 inhibits LPS-induced TLR4 signalling in a competitive manner.  
 The endogenous opioids DYN 3-14 is a potential TLR4 antagonist.  
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Abstract  
Dynorphin 1-17 (DYN 1-17) is biotransformed rapidly to a range of fragments in rodent 
inflamed tissue with dynorphin 3-14 (DYN 3-14) being the most stable and prevalent. DYN 
1-17 has been shown previously to be involved in the regulation of inflammatory response 
following tissue injury, in which the biotransformation fragments of DYN 1-17 may possess 
similar features. This study investigated the effects of DYN 3-14 on lipopolysaccharide 
(LPS)-induced nuclear factor-kappaB/p65 (NF-κB/p65) nuclear translocation and the release 
of pro-inflammatory cytokines interleukin-1beta (IL-1β) and tumor necrosis factor-alpha 
(TNF-α) in differentiated THP-1 cells. Treatment with DYN 3-14 (10 nM) resulted in 35% 
inhibition of the LPS-induced nuclear translocation of NF-κB/p65. Furthermore, DYN 3-14 
modulated both IL-1β and TNF-α release; inhibiting IL-1β and paradoxically augmenting 
TNF-α release in a concentration-independent manner. A number of opioids have been 
implicated in the modulation of the toll-like receptor 4 (TLR4), highlighting the complexity 
of their immunomodulatory effects. To determine whether DYN 3-14 modulates TLR4, 
HEK-Blue™-hTLR4 cells were stimulated with LPS in the presence of DYN 3-14. DYN 3-
14 (10 µM) inhibited TLR4 activation in a concentration-dependent fashion by suppressing 
the LPS signals around 300-fold lower than LPS-RS, a potent TLR4 antagonist. These 
findings indicate that DYN 3-14 is a potential TLR4 antagonist that alters cellular signaling 
in response to LPS and cytokine release, implicating a role for biotransformed endogenous 
opioid peptides in immunomodulation. 
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Introduction  
Innate immune cells such as macrophages are directed immediately to the inflamed site and 
conferred as the first line of defense against invading pathogens or tissue injury [1]. 
Recognition of pathogen-associated molecular patterns by pattern-recognition receptors 
(PRRs) expressed on innate immune cells results in multiple intracellular signalling cascades 
and release of various inflammatory-related effector molecules [2]. Of the PRRs, toll-like 
receptor 4 (TLR4) is extensively studied and the best-characterized human homologue of the 
Drosophila toll. TLR4 specifically recognizes bacterial endotoxin lipopolysaccharide (LPS), 
the major component of the outer membrane of Gram-negative bacteria [3]. The recognition 
of LPS by TLR4 is facilitated by accessory molecules including myeloid differentiation 2 
(MD2) and also CD14 that functions solely as a ligand-binding protein for LPS [4]. 
Engagement of LPS to MD2/TLR4 complexes triggers the classical nuclear factor-kappa B 
(NF-κB) signalling cascades, the main target of TLR4 activation. This, in turn results in the 
translocation and transcription of NF-κB-driven cellular signals in immune cells, producing 
downstream synthesis and release of pro-inflammatory cytokines including tumor necrosis 
factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and interleukin-8 (IL-8) 
[5].    
 
Dynorphin 1-17 (DYN 1-17) is a 17-residue endogenous opioid peptide derived from 
prodynorphin precursors found in mammalian tissues. Our previous studies have 
demonstrated that DYN 1-17 undergoes biotransformation in rodent inflamed tissue, resulting 
in a unique set of opioid and non-opioid fragments [6]. DYN 1-17 and its N-terminal 
biotransformation fragments have been shown to be involved in the modulation of LPS-
induced NF-κB/p65 nuclear translocation and the subsequent release of IL-1β and TNF-α in 
THP-1 cell-derived macrophages through the kappa-opioid receptor (KOR) pathway [7]. In 
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addition to the well-described analgesic effects, DYN 1-17 and its major biotransformation 
fragments have been shown to be involved in the regulation of cellular and humoral immune 
responses.[8, 9]. Structurally related fragments of DYN 1-17 have been demonstrated to 
enhance the LPS- or interferon-gamma (IFN-γ)-stimulated tumouricidal effect in murine 
macrophages [10], triggering the zymosan-mediated oxidative burst in the macrophage cell 
line J774 [11] and suppression of the natural killer cells and antigen-specific cytolytic T-cell 
activity [12] upon engagement with the respective opioid receptors.  
 
Evidence suggests that the immunomodulatory role of opioids in both innate and adaptive 
immunity [13] is due to the presence of classical opioid receptors on both the central immune 
cells (microglia and astrocytes) and peripheral immune cells (macrophages, lymphocytes and 
T cells) [14]. Nevertheless, non-opioid receptor sites have also been reported to be implicated 
in opioid-induced immunomodulation. For instance, morphine at micromolar concentrations 
was found to inhibit the LPS-induced interleukin-6 (IL-6) and TNF-α release associated with 
attenuation of NF-κB activation in mouse peritoneal macrophages. This effect however was 
not reversed by naloxone, indicating the involvement of a non-opioid receptor mechanism 
[15]. Furthermore, inhibition of LPS-induced NF-κB activation and subsequent IL-1β release 
following naloxone treatment in RAW264 cells was mediated by L-type calcium channels 
[16]. The enhancement of phagocytosis by DYN 1-17 in mouse peritoneal macrophages was 
reported to be dependent on intracellular calcium signalling [17], whereas in another study, 
the inhibition of LPS-induced production of nitric oxide and TNF-α by DYN 1-8 was not 
blocked by the KOR antagonist norbinaltorphimine (nor-BNI), indicative of the involvement 
of non-opioid mechanisms in these inhibitory effects [18].  
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Hutchinson et al. have identified TLR4 as one of the possible sites for non-opioid receptor 
mediated mechanisms by highlighting a non-stereoselective reversal of neuropathic pain by 
both enantiomers of the opioid antagonists, naloxone and naltrexone, through inhibition of 
LPS-induced TLR4 signalling [19]. Moreover, morphine non-stereoselectively triggered 
TLR4 signalling in glial cells and this effect was notably blocked by (+)-naltrexone, (+)-
naloxone, and (−)-naloxone, which then shown to be novel TLR4 antagonists. Opioid-
induced MD-2/TLR4 signalling was also observed in vivo using TLR4 knock-out mice [20]. 
Further in silico docking analysis of human MD-2 has identified that MD-2, a potential 
binding site for opioids in the TLR4/MD-2 complex, might implicate the TLR4 as signalling 
pathway. This finding has been subsequently confirmed by structural and functional studies 
[21]. Furthermore, in the absence of LPS, enantiomers of stereoisomeric opioids such as 
morphine and methadone still displayed significant TLR4 activation [20].   
 
Inflammation is activated by LPS binding TLR4, and identifying immune-modulatory roles 
of DYN fragments and underlying mechanisms in LPS-induced activation of pro-
inflammation in peripheral immune cells is essential to better understand the role endogenous 
opioids play in pain and inflammation. In this study, we extend the findings from the 
previous DYN 1-17 biotransformation study by assessing the immunomodulatory effects of 
DYN 3-14 fragment, a fragment produced abundantly in the inflamed tissue homogenate, on 
LPS-induced NF-κB/p65 nuclear translocation and downstream release of pro-inflammatory 
cytokines (IL-1β and TNF-α) in differentiated THP-1 cells. Subsequently, HEK-Blue™-
hTLR4 cells were used to evaluate the involvement of TLR4 activation in mediating these 
effects.  
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Materials and Methods 
Peptide and Reagents 
DYN 3-14 was supplied by Mimotopes Pty. Ltd, Australia with purity greater than 95%. LPS 
from Escherichia coli, serotype O55:B5 was purchased from Enzo Life Sciences 
(Farmingdale, NY, USA), phorbol 12-myristate 13-acetate (PMA) was purchased from 
Adipogen (San Diego, CA, USA) and 4',6-diamidino-2-phenylindole (DAPI) was purchased 
from Cayman Chemical (MI, USA). Primary rabbit monoclonal anti-NF-κB/p65 [E379] 
antibody (ab32536) and goat anti-rabbit IgG H&L (Alexa Fluor 555; ab150078) were 
provided by Abcam (Cambridge, MA, USA). The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) reagent, dimethylsulfoxide (DMSO), N-(3, 5-bis-
trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide (IMD-0354) and foetal bovine serum 
(FBS) were purchased from Sigma Aldrich (St Louis, MO, USA) whereas penicillin-
streptomycin solution, Dulbecco's Modified Eagle's Medium (DMEM) and RPMI 1640 
medium were supplied by Life Technologies (VIC, Australia). Normocin, HEK-Blue 
Selection and QUANTI-Blue™ solution were purchased from Invivogen (San Diego, CA, 
USA).   
 
Cell cultures 
THP-1 cells 
The human monocytic THP-1 cells (ATCC No TIB-202) were maintained as described 
previously [22]. Briefly, THP-1 cells were grown in suspension in RPMI 1640 supplemented 
with 10% FBS, 2 mM L-glutamine, 2 g/L D-glucose, 100 U/mL penicillin and 100 µg/mL 
streptomycin in a humidified atmosphere of 5% CO2 at 37 °C. THP-1 cells were stimulated 
with 50 nM PMA for 48 h to allow differentiation into a functional macrophage-like state. 
Cells were sub-cultured when 80-90 % confluence was reached. 
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HEK-Blue™ hTLR4 cells 
HEK-Blue™ hTLR4 cells comprised of stably transfected HEK-293 cells with human TLR4 
receptor gene, MD2/CD14 co-receptor genes and a reporter plasmid expressing a secreted 
embryonic alkaline phosphatase (SEAP) containing NF-κB response elements. Upon TLR4 
stimulation with LPS, HEK-Blue™-hTLR4 cells activate NF-κB transcription factor and 
subsequently secrete SEAP. A similar protocol for maintaining HEK-Blue™-hTLR4 cell line 
(Invivogen, CA, USA) was followed with slight modifications [23]. Briefly, the cells were 
routinely grown and maintained in DMEM supplemented with 10% heat-inactivated FBS, 2 
mM L-glutamine, 4.5 g/L glucose, 1X HEK-Blue Selection, 100 µg/mL normocin, 50 U/mL 
penicillin and 50 µg/mL streptomycin at 37 °C in 5% CO2. Cells were sub-cultured when 80-
90 % confluence was reached. 
 
NF-κB/p65 translocation assay 
To measure the effects of DYN 3-14 on NF-κB/p65 translocation, differentiated THP-1 cells 
(1.5 x 10
5
cells/mL) were seeded in 96-well black plates and stimulated with LPS (1 μg/mL, 
previously optimised) in the presence of DYN 3-14 at two concentrations (10 nM and 1 µM) 
for 24 h at 37 °C under 5% CO2. Non-stimulated cells received equivalent volume of the 
diluent (sterile ultrapure water), serving as the negative control. To check the functionality of 
the NF-κB/p65 translocation assay, a synthetic, selective NF-κB inhibitor, IMD-0354 (10 µM 
in 0.1% DMSO) was used to treat both LPS- and non-stimulated cells for an hour under 
similar conditions. The corresponding DMSO concentration (0.1%) was prepared accordingly 
as a diluent control for IMD-0354. 
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Treated cells were fixed with freshly prepared cold formaldehyde (3.7%) for 15 min followed 
by incubation in blocking buffer (containing 5% normal goat serum and 0.3% Triton X-100) 
for an hour at room temperature. Primary anti-NF-κB/p65 monoclonal antibody (1:400; 
Abcam, ab32536) was then added into each well and incubated overnight at 4 °C. Next, the 
cells were incubated with secondary Alexa Fluor
®
 555 goat anti-rabbit IgG (H+L) polyclonal 
antibody (1:500; Abcam, ab150078) for 2 h followed by 4',6-diamidino-2-phenylindole 
(DAPI) staining (2 µg/mL) for nucleic acid detection for 10 min at room temperature under 
subdued laboratory lighting. Cells were washed with PBS in triplicate between the 
incubations. Images of the experimental plates were acquired using the widefield 
ImageXpress
®
 Micro XLS automated high-content imaging system (Molecular Devices, CA, 
USA). Four fields of view (2000 pixel × 2000 pixel each) were captured from each well with 
a 10× Plan Fluor (NA 0.3) objective. Acquired images were analysed using a customised 
Translocation-Enhanced application module built in the MetaXpress
®
 version 6.1 image 
analysis software (Molecular Devices, CA, USA). NF-κB/p65 immunofluorescence derived 
from the images at the nuclear level, as identified by DAPI staining, was evaluated as 
positive DAPI overlapping pixels. The number of overlapping pixels in NF-κB/p65 (green) 
images and DAPI (blue) images from each cellular nuclear area obtained from multiple 
images were determined and logged into an Excel spreadsheet.  
 
Cell viability assay 
The effect of DYN 3-14 on the viability of THP-1 cells was assessed using the colorimetric 
MTT assay. Cells (5 x 10
5
 cells/mL) were seeded in 24-well culture plates and incubated with 
a low (10 nM) and high (1 µM) concentration of DYN 3-14 for 24 h followed by incubation 
with the MTT reagent (2.5 mg/mL) for another 2 h at 37 °C. Cells incubated with culture 
medium alone served as the positive control for this assay. The formazan crystals were 
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dissolved with DMSO and 100 µL of each sample was transferred in duplicate into a 96-well 
plate. Wells containing DMSO only in equivalent volume were used as blank. The optical 
density of the produced intracellular formazan, proportional to the number of viable cells 
present, was read spectrophotometrically at 590 nm using iMark™ microplate absorbance 
reader (Bio-Rad Laboratories, CA, USA). The average viable cell value after blank 
absorbance subtraction was calculated as a fraction of the average value obtained from cells 
incubated with medium alone. 
 
IL-1β and TNF-α AlphaLISA immunoassay 
Differentiated THP-1 cells (2 x 10
5
 cells/mL) were seeded in 96-well plates and stimulated 
with 1 µg/mL LPS [7] to release IL-1β and TNF-α in combination with DYN 3-14 at various 
concentrations as indicated in the figure at 37 °C under 5% CO2. The level of human IL-1β 
and TNF-α release was quantified using AlphaLISA kit (Perkin Elmer, VIC, Australia) 
according to the manufacturer’s protocol. At the end of the 24 h treatment period with DYN 
3-14, 1 µL of standard or culture supernatant was added to a 384-well white microplate in 
duplicate followed by addition of 4 µL/well of MIX solution. The MIX solution consists of 
25 µg/mL AlphaLISA anti-analyte acceptor beads and 2.5 nM biotinylated antibody anti-
analyte were prepared in 1X AlphaLISA immunoassay buffer. The microplate was incubated 
for 60 min at 23 °C on an orbital shaker (Ratek Instruments, VIC, Australia) with gentle 
continuous agitation under under subdued laboratory lighting. To detect the assay signal, 5 
μL streptavidin-coated donor beads solution (80 µg/mL) were added into each well and the 
assay microplate was incubated for an additional 30 min at room temperature. The 
AlphaLISA signal was then read using an EnSpire
®
 Alpha 2390 plate reader equipped with 
AlphaScreen
®
 module (Perkin Elmer, VIC, Australia), where the bead complex was excited 
to 680 nm and the emission signals were collected at 615 nm. The unknown analyte 
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concentration was determined using a variable slope regression analysis to fit the data points 
to a standard curve.   
 
TLR4 signalling assay 
To assess TLR4 signalling correlation with NF-κB activation through SEAP production, 
HEK-Blue™-hTLR4 cells (2 x 105 cells/mL) were seeded in each well of 96-well plates (200 
µL volume). The concentration-response curve for LPS-induced TLR4 activation was 
initially determined by stimulating the cells with 10
-13
 - 10
-6
 M of LPS for 24 h at 37 °C. The 
efficacy of DYN 3-14 (10 µM) LPS-RS (6.7 nM), a potent TLR4 inhibitor, on LPS 
concentration-response curve was determined under similar conditions. The molecular weight 
of LPS-RS was calculated to be 1497.8 Dalton. Using LPS submaximal concentration at 1 
ng/mL, the potency of both compounds compared by constructing concentration-inhibitory 
response curves. The SEAP levels were determined with a colorimetric enzyme assay, 
QUANTI-Blue™ (Invivogen, CA, USA) according to the manufacturer’s protocol and the 
optical density was measured at 655 nm wavelength using iMark™ microplate absorbance 
reader (Bio-Rad Laboratories, CA, USA).  
 
Statistical analysis 
All experiments were performed in triplicate and repeated in at least three independent 
experiments. Data are presented as mean + standard error of the mean (SEM). GraphPad 
Prism
®
 6.07 (GraphPad Software Inc, USA) was used for all data analysis. Multiple 
comparisons between groups were analysed using one-way ANOVA followed by Bonferroni 
post-hoc test. Non-linear regression was used to plot and analyze concentration-response 
curves and to obtain estimates for IC50. P values < 0.05 were considered as statistically 
significant.   
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Results 
DYN 3-14 inhibits NF-κB/p65 nuclear translocation in LPS-stimulated THP-1 cells  
The LPS-induced NF-κB/p65 nuclear translocation in THP-1 cell-derived macrophages was 
observed qualitatively upon immunolabelling of the cells with NF-κB/p65 primary antibody. 
Representative images of non-stimulated cells are illustrated in the top panel of Fig. 1 (panel 
A, B and C). In the absence of LPS, p65 subunit of NF-κB (green) was observed 
predominantly in the cytoplasm (Fig. 1, panel B). Further LPS stimulation resulted in a 
distinct nuclear labelling of NF-κB/p65 in stimulated cells (Fig. 1, panel E), reflecting the 
translocation of cytosolic NF-κB/p65 protein into the nuclei. Measurement of NF-κB/p65 
nuclear translocation index showed that LPS induced more than 50% of NF-κB/p65 protein 
translocation into the nuclei compared to the non-stimulated cells (p < 0.05), confirming that 
LPS stimulation resulted in NF-κB/p65 translocation to the nucleus in PMA-differentiated 
THP-1 cells. The modulatory effects of DYN 3-14 at 10 nM and 1 µM on were then 
measured in both non-stimulated and LPS-stimulated THP-1 cells. Co-incubation of LPS 
with DYN 3-14 at both low and high concentrations significantly inhibited NF-κB/p65 
nuclear translocation when compared to the LPS control group (Fig. 2). DYN 3-14 at 10 nM 
displayed the greatest inhibitory effect on LPS-induced NF-κB/p65 nuclear translocation 
(approximately 33%), comparable to IMD-0354, a potent NF-κB inhibitor. DYN 3-14 (at 10 
nM and 1 µM) and IMD-0354 had no significant effect on the basal level of NF-κB/p65 
nuclear translocation in the absence of LPS stimulation (LPS, 100.00 ± 0.60; DYN 3-14 at 10 
nM, 100.07 ± 1.53; at 1 µM, 100.47 ± 1.56; IMD-0354, 100.63 ± 1.63; p > 0.05).  
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Fig. 1 LPS-induced NF-κB/p65 nuclear translocation in differentiated THP-1 cells. 
Representative microscopy images showing NF-κB/p65 nuclear translocation in non-
stimulated (NS) (A, B and C) and LPS-stimulated THP-1 cells (D, E and F). Cells were fixed, 
permeabilised, stained with anti-NF-κB/p65 rabbit monoclonal antibody and visualized with 
Alexa Fluor
®
 555 goat anti-rabbit IgG (green). The nuclei were counterstained with DAPI 
(blue). LPS-stimulated THP-1 cells showed nuclear translocation of NF-κB/p65 (E). Non-
stimulated THP-1 cells exhibited predominant localization NF-κB/p65 in the cytoplasm (B). 
Images were acquired for each fluorescence channel, using suitable TRITC and DAPI filters 
and a 63× objective. Scale bar: 10 µm.  
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Fig. 2 DYN 3-14 and IMD-0354 attenuate NF-κB/p65 nuclear translocation in LPS-
stimulated THP-1 cells. Differentiated THP-1 cells were co-incubated with DYN 3-14 at 10 
nM and 1 µM and IMD-0345 (10 µM) in the presence of LPS (1 µg/mL). The percentage of 
NF-κB/p65 nuclear translocation is expressed relative to LPS control group. Mean ± SEM is 
shown, n = 5 independent experiments. *p < 0.05, One way ANOVA, Bonferroni post-hoc 
test.  
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Effects of DYN 3-14 on THP-1 cell viability 
Results for cell viability (MTT assay) revealed that incubation with DYN 3-14 did not affect 
cell viability in LPS-stimulated, differentiated THP-1 cells at the concentrations tested (LPS, 
100.00 ± 1.07; DYN 3-14 at 10 nM, 112.30 ± 0.99; at 1 µM, 109.40 ± 7.43; p > 0.05). 
 
DYN 3-14 inhibits LPS-induced IL-1β and augments TNF-α release in differentiated 
THP-1 cells   
To determine the effect of DYN 3-14 on LPS-induced cytokine production, the amount of IL-
1β and TNF-α released from LPS stimulated THP-1 cells was measured. Differentiated THP-
1 cells were co-incubated with 1 µg/mL of LPS in the presence of the DYN 3-14 at 
concentrations of 10
-17
 to 10
-7
 M. LPS alone significantly induced the release of IL-1β and 
TNF-α levels in differentiated THP-1 cells after 24 h when compared to the non-stimulated 
cells [IL-1β: LPS-stimulated, 100.00 ± 1.74; non-stimulated, 3.64 ± 2.91; p < 0.05) and TNF-
α: LPS-stimulated, 100.00 ± 3.29; non-stimulated, 2.25 ± 0.44; p < 0.05)]. In the presence of 
DYN 3-14, the induction of IL-1β release by LPS was significantly inhibited at 10-17 to 10-11 
M in a concentration-independent manner (Fig. 3A, p < 0.05). In contrast, DYN 3-14 at 
concentrations of 10
-11
 to 10
-7
 M further augmented the LPS-induced TNF-α levels in 
differentiated THP-1 cells (Fig. 3B, p < 0.05). The other concentrations of DYN 3-14, 
however did not display any significant modulation on IL-1β or TNF-α release following 
LPS stimulation. Treatment with DYN 3-14 alone without LPS showed no effect on both 
cytokine levels (data not shown).  
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Fig. 3 Effect of DYN 3-14 on LPS-induced (A) IL-1β and (B) TNF-α release. 
Differentiated THP-1 cells were stimulated with LPS (1 µg/mL) in the presence of DYN 3-14 
(10
-17
 to 10
-7
 M) for 24 h. IL-1β and TNF-α levels were measured from supernatants using the 
IL-1β and TNF-α AlphaLISA assays, respectively. The AlphaLISA signal was read using an 
Enspire-Alpha 2390 Multilabel Plate Reader. The release of IL-1β and TNF-α in the 
treatment group were normalised and expressed relative to LPS-stimulated control group. 
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Mean ± SEM is shown, n = 5 independent experiments. *p < 0.05, One way ANOVA, 
Bonferroni post-hoc test.  
Effects of DYN 3-14 on the LPS-induced TLR4 signalling in HEK-Blue
TM
 hTLR4 cells   
TLR4 selectively recognizes LPS, leading to downstream inflammatory-related intracellular 
responses including translocation of NF-κB and release of pro-inflammatory cytokines [24]. 
To investigate a specific interaction of DYN 3-14 on TLR4 activity following LPS 
stimulation, HEK-Blue
TM
 cells that stably overexpressed TLR4 were employed. The 
concentration-dependent effects of LPS at TLR4 reached a maximal response at 10
-6
 g/mL of 
LPS (Fig. 4, solid line), with an EC50 of 0.46 + 1.05 ng/mL. The TLR4 antagonistic effects of 
DYN 3-14 (10 µM) and LPS-RS (6.7 nM) were assessed against concentration-response 
curves for LPS. DYN 3-14 shifted the LPS concentration-response curve to the right with a 
higher EC50 value of 0.78 + 1.08 ng/mL (Fig. 4, dashed line). LPS-RS resulted in a greater 
shift to the right with an EC50 value of 1.42 + 1.07 ng/mL (Fig. 4, dotted line). The F-test 
with a value of 74.82 rejected the null hypothesis, indicating that the log EC50 values for each 
slope are different from LPS. Both DYN 3-14 and LPS-RS, achieved similar maximal 
inhibition of LPS induced TLR4 activation at 10
-6
 g/mL, indicating that are both full 
antagonists for the TLR4 receptor complex. To investigate the concentration dependent 
effects of the antagonists, a submaximal concentration of LPS was utilized (1 ng/mL). DYN 
3-14 (Fig. 5) displayed a lower potency than LPS-RS, (IC50=1.42 µM vs IC50=5.09 nM, 
respectively) in the inhibition of LPS-induced TLR4 activation, however LPS was fully 
inhibited for both DYN 3-14 and LPS-RS. DYN 3-14 alone had no effect on TLR4 signalling 
in the absence of LPS (data not shown).  
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Fig. 4 Effects of DYN 3-14 and LPS-RS on LPS-induced TLR4 signalling. HEK-Blue™-
hTLR4 reporter cell lines were stimulated with LPS alone (concentrations ranging from 10
-12
 
to 10
-6
 g/mL), with combination of LPS and DYN 3-14 (10 µM) or with combination of LPS 
and LPS-RS (6.7 nM) for 24 h. The percentage of maximal response of TLR4 activation in 
each treatment group was normalized and expressed relative to LPS alone-stimulated control 
group. Mean ± SEM is shown, n = 7 independent experiments, EC50 was assessed using non-
linear regression.  
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Fig. 4 Inhibition curves for DYN 3-14 and LPS-RS on LPS-induced TLR4 activation. 
HEK-Blue™-hTLR4 reporter cell lines were stimulated with LPS 1 ng/mL and treated with 
DYN 3-14 (10
-8
 – 10-5 M) or LPS-RS (10-12 – 10-7 M) for 24 h. The percentage of maximal 
response of TLR4 activation in each treatment group was normalized and expressed relative 
to LPS control group. Mean ± SEM is shown, n = 4 independent experiments, IC50 assessed 
using non-linear regression.  
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Discussion   
This study investigates the modulatory effect of the non-opioid DYN 1-17 fragment, DYN 3-
14, on NF-κB activation and subsequent downstream release of pro-inflammatory cytokines. 
DYN 1-17 is released by leukocytes in inflamed tissue and plays an important role in 
regulating inflammatory pain [25]. Biotransformation resulting in the removal of the amino-
terminal tyrosine (Tyr) residue in opioid peptides yields fragments that are structurally “non-
opioid” in nature with very low affinity for opioid receptors [26]. The immunoregulation 
observed may be facilitated by a range of opioid and non-opioid fragments, produced 
following biotransformation of DYN 1-17 at the site of inflammation [6]. Outside of 
traditional opioid receptor-mediated effects, evidence of non-opioid receptors roles for opioid 
peptides include action at melanocortin receptors [27, 28], bradykinin receptors [29], N-
methyl-D-aspartate (NMDA) receptor complex [30] and recently the TLR4 [20], therefore the 
overarching effects of biotransformed opioid peptides may involve a number of possible 
mechanisms. It is likely that DYN 3-14, the most abundant fragment of DYN 1-17 produced 
in inflamed tissue, modulates inflammatory responses through one of these mechanisms.  
 
IL-1β and TNF-α were released in response to LPS treatment, consistent with the previously 
reported cytokine expression profile in differentiated THP-1 cells following LPS stimulation 
[31]. Herein, we demonstrated that DYN 3-14 modulated IL-1β and TNF-α differentially. 
While the release of IL-1β was reduced following incubation with DYN 3-14 (10-11 to 10-17 
M), DYN 3-14 further elevated TNF-α release induced by LPS in differentiated THP-1 cells. 
An earlier study has shown that DYN fragments at low concentrations (10
-16
 to 10
-12
 M) 
significantly modulated LPS-induced TNF-α and nitric oxide by inhibiting the production of 
these inflammatory mediators in mouse primary mixed glia cultures, implicating the 
involvement of a novel ultrahigh-affinity receptor in mediating these inhibitory effects [18]. 
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Supporting this notion, significant opioid peptide actions on immune cells at ultralow 
concentrations also have been reported in a number of experimental studies in a range of cell 
types [32-34].  
 
The differential effects seen on cytokine release in this study are consistent with evidence 
from a previous study, showing that β-endorphin and naltrindole elevated IL-1β production 
and suppressed TNF-α level in LPS-stimulated peripheral blood monocytes [35]. The 
differential secretion of TNF-α and IL-1β following LPS induction in isolated mouse 
macrophages further describes the complexity of cytokine modulation by immune cells [36]. 
LPS-induced TNF-α production is regulated by a number of intracellular signal transduction 
pathways, including the activation of mitogen-activated protein kinase (MAPK) family [37]. 
LPS is able to induce extracellular-signal-regulated kinase-1 (ERK1) and ERK2, c-Jun N-
terminal kinases (JNKs) and p38, which results in increased TNF-α translation [38, 39]. 
Activation of ERK also leads to transcription of c-Fos and AP-1 formation [40]. Interestingly, 
several AP-1 binding regions have been identified on the TNF-α promoter, thus TNF-α 
secretion is also elicited through an AP-1 transcription factor [37, 41]. It is possible that, 
DYN 3-14 promotes ERK-dependent expression of AP-1 proteins, resulting in elevation of 
TNF-α level in differentiated THP-1 cells, this however requires further investigation to 
confirm.  
 
Differential effects of DYN 3-14 on both IL-1β and TNF-α release suggests that this peptide 
is a biased antagonist at TLR4. Biased ligand refers to ligands that are able to stabilize 
multiple unique receptor confirmations, resulting in collateral activation of multiple 
intracellular pathways produced by interaction of different cellular coupling proteins [51]. 
Another example of a biased ligand is the β-blocker propranolol. It is an ERK activator and at 
  
22 
 
the same time inversely agonizes Gs alpha subunit (Gsα)-mediated cAMP formation, denoting 
that some ligands can be agonists for some pathways and antagonists for others [52]. The 
concept of biased ligand represents a novel approach for the development of more effective 
and better tolerated drugs as differential effects on cellular inflammatory processes may have 
implication clinically. 
 
In this study, the increased nuclear labelling of NF-κB/p65 (green) following LPS stimulation 
reflects the translocation of cytosolic NF-κB/p65 into the nuclei. Under resting conditions, 
inactive NF-κB is bound to its inhibitory protein, the IκB protein in the cytoplasm. Activation 
of the IKK complex by LPS phosphorylates the IκB protein, releasing the NF-κB complex 
followed by translocation into the nucleus [42]. Engagement of the NF-κB complex with 
DNA promoter regions in the nucleus then leads to transcription and expression of various 
inflammatory mediators including cytokines [43]. DYN 3-14 was shown in this study to 
attenuate NF-κB/p65 nuclear translocation in LPS-stimulated THP-1 cells, comparable to that 
of the selective IKBα phosphorylation inhibitor, IMD-0354. Moreover, DYN 3-14 had no 
effect on the viability of THP-1 cells, excluding non-specific cytotoxicity as a possible 
explanation for the NF-κB/p65 inhibition. NF-κB has been implicated in the regulation of a 
plethora of genes involved in inflammation; inhibition of NF-κB/p65 nuclear translocation 
will eventually terminate the transcription of pro-inflammatory genes in the activated 
macrophages, thereby limiting the severity of an inflammatory response [44].  
 
The activation of NF-κB by LPS is principally mediated through the TLR4 receptor [5, 45]. 
A number of studies have reported the involvement of numerous opioids in modulation of 
TLR4 signalling pathway [46-48]. For this reason, HEK-Blue™-hTLR4 cells were used to 
elucidate the mechanism underlying the modulation non-opioid DYN fragments, as these 
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cells overexpress TLR4 receptors. LPS from Escherichia coli O111:B4 was used to stimulate 
the inflammatory response and this compound specifically activates TLR4 selectively [49], 
excluding the involvement of other TLRs. This study showed that DYN 3-14 blocks LPS-
induced TLR4 signalling in the HEK-Blue™-hTLR4 cells, which provides a mechanistic 
insight into the inhibition of NF-κB/p65 translocation seen with the DYN 3-14 in the 
differentiated THP-1 cells. The selectivity of the modulatory effect of DYN 3-14 at TLR 
other than TLR4 has not been explored. However, other biotransformed fragments including 
a range of non N-terminal dynorphin-related peptides such as DYN 2-17, DYN 6-12, DYN 7-
17 and DYN 3-6 have been investigated utilizing the TLR4 overexpressed HEK cells but 
none of these fragments modulated TLR4 signalling, providing some insights into the 
selective nature of DYN 3-14 action (data not shown).  
 
LPS-RS, derived from Rhodobacter sphaeroides is a potent competitive inhibitor of LPS at 
TLR4 in both human and murine cells [50]. LPS in the presence of DYN 3-14 or LPS-RS 
revealed that both compounds are capable of complete inhibition of LPS effects on TLR4. 
LPS-RS, however, exhibits a higher potency in comparison to DYN 3-14 as an antagonist of 
LPS-induced TLR4 signalling. In congruence with the lower potency exhibited by DYN 3-
14, this peptide was produced abundantly following biotransformation of DYN 1-17 in rodent 
inflamed tissue homogenate [6]. Furthermore, DYN 3-14 does not undergo rapid degradation 
(93.40% remaining after 1 h, data not shown) upon incubation with THP-1 cells, suggesting 
that high local concentrations are present in the inflammatory milieu. In addition, DYN 3-14 
at higher concentrations (10 µM) inhibited LPS-induced TLR4 signalling in overexpressing 
TLR4 cells. Taken together, it can be postulated that DYN 3-14 may be produced in high 
quantities at localized sites of inflammation resulting in anti-inflammatory effects.   
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In conclusion, this study provides a mechanistic insight into biotransformed endogenous 
opioid peptide of DYN 1-17 involvement in immunomodulation and highlights a possible 
new avenue for therapeutic intervention. Consistent with the abundant local accumulation of 
DYN 3-14 following biotransformation of DYN 1-17 in rodent inflamed tissue [6], this study 
has described a potential role for DYN 3-14 as an endogenous immune modulator in the 
tissue through modulation of pro-inflammatory cytokine release and the action upon TLR4-
mediated NF-κB/p65 pathways. 
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